Aug 252017
 

[Fifa Rahman for IP-Watch, Link (CC-BY-SA)]  Gilead’s announcement today that they would include four middle-income countries (Malaysia, Thailand, Belarus, Ukraine) in their sofosbuvir voluntary licence was a welcome surprise, and will enable millions access to their highly effective, but exorbitantly priced, drug.

The decision to include these countries, however, no doubt is a response to increasing pressure from within these countries to either issue a compulsory licence (CL) or a government use licence (GUL), invalidate the sofosbuvir patents, or block data exclusivity for the drug. Continue reading »

Share

The Medicines Patent Pool Signs First Sub-licences for Hepatitis C Medicine Daclatasvir

 Posted by on January 20, 2016  Comments Off on The Medicines Patent Pool Signs First Sub-licences for Hepatitis C Medicine Daclatasvir
Jan 202016
 

logo-MedicinesPatentPoolFour companies to help speed access to curative direct-acting antiviral in 112 low- and middle-income countries

[MPP Press release, Link, (CC-BY-NC-ND)] Geneva, 20 January 2016 The Medicines Patent Pool (MPP) announced its first round of sub-licences for the generic production of Bristol-Myers Squibb’s daclatasvir, a novel direct-acting antiviral that is proven to help cure multiple genotypes of the hepatitis C virus. Generic companies Cipla, Emcure, Hetero and Natco have signed non-exclusive, royalty free agreements with Bristol-Myers Squibb and the MPP to produce and sell daclatasvir in 112 low- and middle-income countries. Continue reading »

Share

Medicines Patent Pool Expands Mandate to Hepatitis C and Tuberculosis Treatment

 Posted by on November 6, 2015  Comments Off on Medicines Patent Pool Expands Mandate to Hepatitis C and Tuberculosis Treatment
Nov 062015
 

logo-MedicinesPatentPoolMPP’s voluntary licensing work could benefit millions of patients in low- and middle-income countries

[MPP Press Release, September 6, 2015]  The Medicines Patent Pool (MPP), the world’s only voluntary licensing mechanism in public health, announced an expansion of its mandate today to hepatitis C and tuberculosis medicines. The UNITAID Executive Board, meeting November 4-5 in Geneva, approved the MPP’s proposals to improve access to both life-saving direct acting antivirals (DAAs) to treat hepatitis C and new and re-purposed medicines for tuberculosis. UNITAID created the MPP in 2010 to provide better health options for people living with HIV. To date, MPP has signed agreements for 12 antiretrovirals (ARVs) for countries home to 87-93% of people living with HIV in the developing world. Continue reading »

Share

The Medicines Patent Pool Signs Licensing Agreement with MSD for Paediatric Formulations of Raltegravir

 Posted by on February 24, 2015  Comments Off on The Medicines Patent Pool Signs Licensing Agreement with MSD for Paediatric Formulations of Raltegravir
Feb 242015
 

medicines patent poolCompany joins five other MPP patent holders in efforts to improve HIV paediatric care

[Reposted from the Medicines Patent Pool, Link, (CC-BY-NC-ND)]  The Medicines Patent Pool (MPP) announced a licence today with MSD, known as Merck in the United States and Canada, for paediatric formulations of raltegravir, a key medicine approved for children living with HIV four weeks of age and older. With the new licence, generic manufacturers and other companies based anywhere in the world can develop, manufacture and sell low cost, paediatric versions of raltegravir in countries with the highest burden of disease, where 98 percent of children with HIV in the developing world live. Continue reading »

Share
Aug 052013
 

medicines patent poolFocus on Preventing Blindness in People Living with HIV

[MPP Press Release, Link, (CC BY-NC-ND)]  The Medicines Patent Pool and Roche today announce an agreement to increase access in developing countries to valganciclovir, a key easy-to-take oral medicine to treat cytomegalovirus (CMV), a viral infection that can cause blindness in people living with HIV. Continue reading »

Share